Clinical Trials Browser

Carcinoma, Transitional Cell

Sarcoma, Kaposi

Squamous Cell Carcinoma of Head and Neck

Liposarcoma, Neoplasms, Sarcoma

Prostatic Neoplasms

Clear-cell metastatic renal cell carcinoma, Carcinoma, Renal Cell, Kidney Neoplasms

Brain Neoplasms, Carcinoma, Renal Cell

Glioblastoma

Pancreatic Neoplasms

Prostatic Neoplasms

Breast Neoplasms

Triple Negative Breast Neoplasms

Glioblastoma

Inflammatory Breast Neoplasms, Triple Negative Breast Neoplasms

Colorectal Neoplasms

Colonic Neoplasms

Multiple Myeloma

Carcinoma, Transitional Cell

Thyroid Neoplasms

Breast Neoplasms, Neoplasm Metastasis

Carcinoma, Transitional Cell

Subcutaneous panniculitis-like T-cell lymphoma, Immunoblastic Lymphadenopathy, Lymphoma, T-Cell, Enteropathy-Associated T-Cell Lymphoma

Squamous Cell Carcinoma of Head and Neck

Cardiovascular Diseases, Hematologic Diseases, Immune System Diseases, Multiple Myeloma, Neoplasms

Carcinoma, Non-Small-Cell Lung

Brain Neoplasms, Triple Negative Breast Neoplasms

Breast Neoplasms, Lung Neoplasms, Neoplasms, Ovarian Neoplasms, Pancreatic Neoplasms

Squamous Cell Carcinoma of Head and Neck, Melanoma

Endometrial Neoplasms

Multiple Myeloma

Breast Neoplasms, Triple Negative Breast Neoplasms

Inflammatory Breast Neoplasms, Triple Negative Breast Neoplasms

Carcinoma, Renal Cell

Brain Neoplasms, Breast Neoplasms, Central Nervous System Diseases

Hematologic Neoplasms

Multiple Myeloma

Carcinoma, Non-Small-Cell Lung

Adenocarcinoma Of Esophagus, Esophageal Squamous Cell Carcinoma

Carcinoma, Non-Small-Cell Lung, Lung Neoplasms

Endometrial Neoplasms

Carcinoma, Transitional Cell

Colorectal Neoplasms

Recurrence, Lymphoma, Large B-Cell, Diffuse

Clinical Trials

N-803 in Combination With Pembrolizumab and Enfortumab Vedotin for Treatment of Urothelial Cancer

PULSAR

NovoTTF-200A + Pembrolizumab In Melanoma Brain Metastasis

Phase I/II Open Label Study Evaluating the Safety and Efficacy of Combining STAT3 Inhibition (TTI-101) With Anti-PD-1 Therapy (Pembrolizumab) in Patients With Recurrent or Metastatic (RM) Head and Neck Squamous Cell Carcinoma (HNSCC)

NeoSarc

Pembrolizumab With Androgen Deprivation Therapy and Radiotherapy for the Treatment of Patients With High Risk Localized Prostate Cancer

PSMA Therapy and Immunotherapy in Kidney Cancer

Study of Lenvatinib Plus Pembrolizumab in IO Refractory mRCC Patients With Brain Metastases

Abemaciclib + Pembrolizumab In Glioblastoma

PRIMUS006

TALON

LN-144

Breast Cancer Vaccine in Combination With Pembrolizumab for Treatment of Persistent, Recurrent, or Metastatic Breast Cancer

SOC-2320

Dendritic Cell-Based Treatment Plus Immunotherapy for the Treatment of Metastatic or Unresectable Triple Negative Breast Cancer

Lenvatinib, Pembrolizumab, and Tumor Treating Fields (TTFields) for Second-line Treatment of Glioblastoma

Randomized Study of Neo-adjuvant and Adjuvant Pembrolizumab With and Without Targeted Blood Brain Barrier Opening Using Exablate MRI-guided Focused Ultrasound (Exablate MRgFUS) for Recurrent Glioblastoma

Panitumumab and Pembrolizumab in Combination With Neoadjuvant Chemotherapy for the Treatment of Stage III-IV Triple Negative Breast Cancer

Pembrolizumab and Autologous Dendritic Cells for the Treatment of Refractory Colorectal Cancer (CRC)

ECT-Pembrolizumab in Patients With Unresectable Melanoma With Superficial or Superficial and Visceral Metastases

Pembrolizumab in Early Stage Colon Cancer

Pembrolizumab as Salvage Therapy for the Treatment of Multiple Myeloma in Patients Progressing on CAR-T Cell Therapy

Naptumomab Estafenatox in Combination With Pembrolizumab Preceded by Obinutuzumab in Patients With Urothelial Cancers

Pembrolizumab and Lenvatinib/Chemotherapy for Poorly Differentiated/Anaplastic Thyroid Cancer

PELICAN

CARMA

Brentuximab Vedotin and Pembrolizumab in Treating Patients With Recurrent Peripheral T-Cell Lymphoma

Re-irradiation With NBTXR3 in Combination With Pembrolizumab for the Treatment of Inoperable Locoregional Recurrent Head and Neck Squamous Cell Cancer

A Study of Pembrolizumab Added to the Standard First-Line Therapy of Cyclophosphamide, Bortezomib, and Dexamethasone (CyBorD) for NDMM NTE

Dose Escalation Trial of Bexmarilimab (FP-1305) Plus Pembrolizumab in Non-Small Cell Lung Cancer

Combination Liposomal Irinotecan and Pembrolizumab For Triple-Negative Breast Cancer (TNBC) With Brain Metastases (BM)

Phase I Study of ZN-c3 and Bevacizumab ± Pembrolizumab in Metastatic CCNE1 Amplified and TP53 Mutant Solid Tumors

GR-MD-02 + Pembrolizumab Versus Pembrolizumab Monotherapy in Melanoma and Squamous Cell Head and Neck Cancer Patients

Sargramostim (GM-CSF) + PD-1

Pembrolizumab With Sitravatinib in Recurrent Endometrial Cancer and Other Solid Tumors With Deficient Mismatch Repair System

Pembrolizumab, Belantamab and Dexamethasone in Refractory Multiple Myeloma.

Radiotherapy in Combo With Chemo and Immunotherapy in Patients With PD-L1 Positive Metastatic TNBC

SGT-53, Carboplatin, and Pembrolizumab for the Treatment of Metastatic Triple Negative Inflammatory Breast Cancer

Optimizing Pembrolizumab Therapy With Timing and Intensification With Axitinib

TOPAZ

64Cu-DOTA-pembrolizumab PET for the Study of PD1 Expression

Study of Dara-Pembro for Multiple Myeloma Patients

HFHS 21-01

Epacadostat and Pembrolizumab Before Surgery in Treating Participants With Stage II-III Esophageal or Gastroesophageal Cancer

Pembrolizumab With or Without Chemotherapy Before Surgery in Treating Patients With Stage I-IIIA Non-Small Cell Lung Cancer

Pilot Trial of SP-2577 Plus Pembrolizumab in Select Gynecologic Cancers

Study of Pembrolizumab and Ramucirumab in Pts With Progressive TCC After Treatment With an Immune Checkpoint Inhibitor

Rintatolimod and Pembrolizumab for the Treatment of Refractory Metastatic or Unresectable Colorectal Cancer

Feasibility Study on Expandion of MILs From NSCLC and SCLC Patients and Infusion With Pembrolizumab

PLACARD